Investments
Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET
Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power
The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.
Read
Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET
Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions
Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.
Read
Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET
Nvidia, Meta Materials, SFC Energy - Strong signs
After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.
Read
Commented by Stefan Feulner on November 28th, 2022 | 10:41 CET
SynBiotic SE, Cardiol Therapeutics, Canopy Growth - Like hitting the jackpot
The final draft of the German government's key issues paper on the legalization of cannabis in Germany is ready, and final approval is likely to be a mere formality. For the companies concerned, this is equivalent to winning the lottery. The global cannabis market is expected to grow by 13.9% annually to USD 64.91 billion between 2022 and 2027. However, these profit increases have yet to reach the stock market. Some companies, for example, are trading below cash, while others lost more than 90% of their value in the correction that has been underway since 2019.
Read
Commented by Stefan Feulner on November 25th, 2022 | 23:16 CET
Viromed Medical AG, Encavis AG, K+S - The foundation is laid
For weeks now, the most important stock markets around the globe have been on an upward trend. What was initially only declared as a countermovement in the overriding downward movement could now be the start of a more pronounced year-end rally. While indices such as the DAX and the Dow Jones have already managed to break out of the downtrends they have been following since the start of the Ukraine war, smaller stocks, in particular, still offer considerable catch-up potential.
Read
Commented by Armin Schulz on November 23rd, 2022 | 12:10 CET
K+S, Defense Metals, RWE - Profiting from stocks that fight shortcomings
The first supply chain problems occurred during the Corona Pandemic. With the outbreak of the Ukraine conflict, further deficiencies of Western countries were exposed. It has been known for a long time that the US and Europe are dependent on raw materials and energy from Russia and China. The Middle Kingdom, in particular, already has a monopoly on critical raw materials such as rare earths and tungsten. There has been a minor trade war between the US and China for some time now. Russia has supplied both Europe and the US with cheap energy. Now in times of tension, the dependencies are coming out in the open. So today, we look at three stocks that can combat the shortage.
Read
Commented by Stefan Feulner on November 22nd, 2022 | 13:42 CET
Favorable starting positions for Commerzbank, Desert Gold and BioNTech
The suspected downward pressure due to uncertainties in the economy and geopolitics has so far failed to materialize. Instead, the most important stock indices, such as DAX or Dow Jones, were able to leave their short-term downward trends and are sending signals for a further upward push. In addition to the stock market, the precious metals sector was also able to turn around. Here, in particular, entry opportunities beckon at a significantly reduced level with the chance of long-term, disproportionate price gains.
Read
Commented by André Will-Laudien on November 22nd, 2022 | 11:53 CET
Triple AAA stocks take off: Amazon, Aspermont, Alphabet, Allianz - Sellout done?
Well, who would have thought: after 9 months of correction mode, the stock market is already returning to normal mode this year. The indicator for leaving the panic mode is the VDAX, i.e. the measured fluctuation range of the index in 12 months. Last week, it reached levels of 22 to 23 again, after peaking at 33 in September. By comparison, in the absolute panic phase at the start of the war, the volatility gauge was 48.6%. The mood has eased, so welcome to the year-end rally. Where are the best opportunities for investors?
Read
Commented by Stefan Feulner on November 21st, 2022 | 11:07 CET
Morphosys, Defence Therapeutics, Evotec - Stabilization after the sell-off
After the publication of the figures for the third quarter, many biotech companies were able to surprise positively. Due to the partly panic-like sell-off in this capital-intensive sector, there are attractive entry opportunities at a strongly discounted level, which should pay off with disproportionate price gains in the long term. The fact that promising companies are already trading below their cash levels shows that the panic is exaggerated. There are currently signs of a bottoming out, which could herald the next upward wave.
Read
Commented by Juliane Zielonka on November 17th, 2022 | 13:48 CET
BioNxt Solutions, Pfizer, Bayer - Biotech and pharma stocks in focus
Pharma and biotech companies are still booming. However, large corporations like Pfizer and Bayer need help maintaining their market dominance with long-term studies and patent extensions. Pfizer, in particular, experienced the rush of speed in recent years thanks to the emergency approval of the Covid-19 vaccine. In hindsight, however, voices are growing louder about the potential long-term damage of this market cut. Multi-million dollar lawsuits may result. Positioning itself in the mental health niche, whose market size was USD 381.98 billion in 2020, is BioNxt Solutions. Their mission: to tackle depression, anxiety and PTSD with natural substances. A look at the data.
Read